Guideline provides evidence-based recommendations for allergists and gastroenterologists focusing on the clinical management of EoE for pediatric and adult patients.
Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus triggered by allergens that causes difficulty with swallowing in adults, which grows more frequent and intense over time, affecting patients’ quality of life. Children experience varied symptoms that include feeding difficulty, pain, vomiting, as well as dysphagia. EoE affects an estimated one in 2,000 people.
A new guideline from the American Gastroenterological Association (AGA) and the Joint Task Force for Allergy-Immunology Practice Parameters provides recommendations for the management of EoE in pediatric and adult patients.
Key guideline highlights:
- Topical steroids are recommended as a first-line treatment for EoE.
- The guideline also recommends proton pump inhibition (PPI) therapy, diet therapy and esophageal dilation as treatment options.
- The use of novel, targeted biologic therapies for EoE are being actively evaluated and more research is needed before these can be recommended.
Review the guideline for the complete recommendations.
This guideline was developed through a collaboration between AGA and the Joint Task Force for Allergy-Immunology Practice Parameters, which comprises the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology. This guideline is jointly published in Gastroenterology, the official journal of the AGA Institute, and Annals of Allergy, Asthma and Immunology, the scientific journal of the American College of Allergy, Asthma & Immunology. Learn more about EoE in the AGA GI Patient Center.